1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Universal Ibogaine Inc.
  6. News
  7. Summary
    IBO   CA69379R1082

UNIVERSAL IBOGAINE INC.

(IBO)
End-of-day quote Bourse de Toronto  -  2022-08-09
0.0350 CAD    0.00%
06/29Universal Ibogaine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022
CI
06/28Nick Karos to Present at H.C. Wainwright 1st Annual Mental Health Conference
AQ
06/24Nick Karos to Present at H.C. Wainwright 1st Annual Mental Health Conference
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

UNIVERSAL IBOGAINE Engages Investor Relations Firm Blue Digital Media

06/13/2022 | 06:21pm EDT

(via TheNewswire)

Universal Ibogaine Inc.


Calgary, ABTheNewswire -June 13, 2022Universal Ibogaine Inc.(TSXV:IBO),(OTC:IBOGF)and(FSE:JC4) (“UI” or the “Company”) a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model advises it has engaged investor communications firm Blue Digital Media & Web Solutions (“Blue Digital”) for assistance with expanding awareness of UI’s business activities.

Blue Digital will provide expandeddistribution of the UI story across multiple channels and audiences.  The expected result is increased awareness of UI’s  plans for research into utilizing ibogaine as part of the delivery of a continuum of care treating opioid abuse and other addictions.

Blue Digital will receive compensation of USD 27,000 for a 3 month engagement effective June 13, 2022.  In addition, Blue Digital will receive a total of 450,000 stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a term of 3 years to expiry, and vesting one-third at the end of each month of the term of service.

Nick Karos, UI’s Chief Executive Officer, noted “We are pleased to have access to Blue Digital’s distribution channels, as their reach across borders will expand awareness of our business to new audiences. Addiction knows no boundaries and so the solution we pursue must also be global in nature.”

About Universal Ibogaine Inc. 

UI is a life sciences company,with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements.    UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.  

 

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct. 

 

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎ 

For further information:  

Investor Relations:Dugan Selkirk, IR Manager 

dugan.selkirk@universalibogaine.com 

Related Links 

https://universalibogaine.com  

 

Copyright (c) 2022 TheNewswire - All rights reserved.

Copyright (c) 2022 TheNewswire - All rights reserved., source Press Releases

All news about UNIVERSAL IBOGAINE INC.
06/29Universal Ibogaine Inc. Reports Earnings Results for the Third Quarter and Nine Months ..
CI
06/28Nick Karos to Present at H.C. Wainwright 1st Annual Mental Health Conference
AQ
06/24Nick Karos to Present at H.C. Wainwright 1st Annual Mental Health Conference
AQ
06/13UNIVERSAL IBOGAINE Engages Investor Relations Firm Blue Digital Media
AQ
06/10Universal Ibogaine Advises of Departure of David Danziger from the Board of Directors
AQ
06/10Universal Ibogaine Inc. Announces Resignation of David Danziger from the Board of Direc..
CI
05/12UNIVERSAL IBOGAINE : Advises Of Departure Of Marilyn Mauritz From Board Of Directors
PU
05/12UNIVERSAL IBOGAINE : Provides Update On Kelburn Recovery Center Operations
PU
04/21Universal Ibogaine Announces Resignation of Marilyn Loewen Mauritz as A Member of the B..
CI
04/21Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Dir..
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -3,87 M -3,03 M -3,03 M
Net Debt 2021 0,27 M 0,21 M 0,21 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 6,68 M 5,23 M 5,23 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float -
Chart UNIVERSAL IBOGAINE INC.
Duration : Period :
Universal Ibogaine Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Nicholas Peter Karos Chief Executive Officer
Greg J. Leavens Chief Financial Officer
Ian Campbell Chairman
Alberto Solß Agullˇ Director
Robert Turner Director
Sector and Competitors